SS Innovations International, Inc 8-K, filed May 30, 2023
SS Innovations International, Inc. (SSII)
About this 8-K
SS Innovations International, Inc filed this 8-K on May 30, 2023.
Items reported
- Item 8.01: Other events
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
|
|
||
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including
area code: (
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each Class | Trading Symbol | Name of each exchange on which registered | ||
| None | N/A | N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
As used in this Current Report on Form 8-K (this “Report”), and unless otherwise indicated, the terms “SSII,” “the Company,” “we,” “us” and “our” refer to SS Innovations International, Inc. f/k/a Avra Medical Robotics, Inc. and its subsidiaries.
Item 8.01 Other Events.
On May 30, 2023, the Company issued a press release providing a corporate update.
A copy of the press release is filed as Exhibit 99.1 to this Report.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description | |
| 99.1 | Press Release dated May 30, 2023 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: May 30, 2023 | SS INNOVATIONS INTERNATIONAL, INC. | |
| By: | /s/ Sudhir Srivastava | |
| Sudhir Srivastava, M.D. Chairman and Chief Executive Officer | ||
2
Exhibit 99.1
SS Innovations International, Inc. Provides Business Update; Celebrates Achievement of Significant Milestones
Company’s flagship SSi Mantra surgical robotic system utilized to perform successful complex cardiac, lung, head
and neck surgeries
SSi Mantra used in first pediatric urology surgery
Robotic surgical system has now completed more than 200 surgeries; clinically validated in India to perform more than 30 different types of surgical procedures
Fort Lauderdale, FL., May 30, 2023 - News Direct - SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making robotic surgery affordable and accessible to a global population, today provides a business update.
Dr. Sudhir Srivastava, Chairman of the Board and Chief Executive Officer of SS Innovations, and a pioneer in robotic cardiothoracic surgery said, “SS Innovations has achieved significant milestones in 2023, which has the potential to be a transformational year for the Company. We are delighted with the progress that has been made as we continue to clinically validate our flagship surgical robotic system, the SSi Mantra.
“SS Innovations has now completed more than 200 surgeries using the SSi Mantra and the system has been validated in India to perform more than 30 different types of surgical procedures, including thoracic and cardiac surgeries.
“Importantly, we are motivated each day by our mission to make robotic surgery, with its reduced risk of pain and infection and shorter recovery times, available to the ‘forgotten world,’ the vast populations throughout the world who currently lack access to this type of precision surgery.”
Operational Highlights
| ● | In May 2023, thoracic surgeons conducted the first-ever lung surgeries using the SSi Mantra. The surgeries, a lower left lobectomy and a pneumonectomy (complete removal of the lung), pericardial window (removal of a portion of the pericardium), and a complex thymectomy (removal of the thymus) were carried out successfully at the Narayana Hrudayalaya Health City in Bengaluru, India. |
| ● | Also in May, the Company’s CEO and Chairman, Dr. Sudhir Srivastava, performed a world-first robotic cardiac surgery using the SSi Mantra surgical robotic system at Continental Hospitals, Hyderabad. Additionally, Dr. Srivastava, a pioneer in robotic cardiac surgery, performed two bypass procedures at the world renowned Narayana Hrudayalaya Institute of Cardiac Sciences which is famed for doing a high volume of cardiac surgeries daily. There, he also taught many of the senior surgeons, fellows and residents the techniques that he had pioneered in the past performing many “World First” robotic cardiac surgical procedures. |
| ● | Surgeons at the Rajiv Gandhi Cancer Institute completed the center’s 100th robotic surgery, a successful radical prostatectomy, using the SSi Mantra surgical robotic system. |
| ● | In April 2023, the SSi Mantra was utilized to successfully perform the first pediatric pyeloplasty surgery on a 5-year-old boy at Hindusthan Hospital, Coimbatore. |
| ● | Also in April, skilled surgeons performed the first head and neck surgery at Medanta Medicity in Gurugram, Haryana. The Trans Oral Robotic Surgery (TORS) was performed to remove a cancerous mouth lesion. |
| ● | In March 2023, the SSi Mantra was utilized in a Thymectomy Surgery at Continental Hospitals, Hyderabad. The robotic procedure offered several advantages over traditional surgery with minimal trauma, and faster recovery. |
SS Innovations completed a merger with AVRA Medical Robotics, Inc., in April 2023 and began trading its common stock on OTC Markets under the ticker symbol “SSII”.
About SS Innovations International, Inc.
SS Innovations International, Inc. (OTC: SSII) is a developer of innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger part of the global population. SSII’s product range includes its proprietary “SSI Mantra” surgical robotic system, and “SSI Mudra”, its wide range of surgical instruments capable of supporting a variety of surgical procedures including robotic cardiac surgery. SSII’s business operations are headquartered in India and SSII has plans to expand the presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions, globally. For more information, visit SSII’s website at ssinnovations.com or LinkedIn for updates.
Forward-Looking Statements
This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or SS Innovations International’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.
For more information:
PCG Advisory
Stephanie Prince
sprince@pcgadvisory.com
(646) 863-6341